Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 26;13(11):2613.
doi: 10.3390/cancers13112613.

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium

Eva Obermayr  1 , Angelika Reiner  2 , Burkhard Brandt  3   4 , Elena Ioana Braicu  5 , Alexander Reinthaller  1 , Liselore Loverix  6 , Nicole Concin  7 , Linn Woelber  8 , Sven Mahner  8   9 , Jalid Sehouli  5 , Ignace Vergote  6 , Robert Zeillinger  1
Affiliations

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium

Eva Obermayr et al. Cancers (Basel). .

Abstract

Introduction: We previously reported the prognostic impact of circulating tumor cells (CTCs) in a multicenter study on minimal residual disease in primary ovarian cancer. With additional follow-up data, we evaluated the combined CTC approach (CTCscombo), in particular for the patients who had survived more than five years.

Material and methods: Blood samples taken at baseline and six months after adjuvant treatment (follow-up) were assessed by quantitative PCR (qPCR) measuring PPIC transcripts and immunofluorescent staining (IF). A positive result with either IF or qPCR was classified as CTCcombo-positive. Further, PPIC was assessed in the primary tumor tissue.

Results: The concordance of IF and qPCR was 65% at baseline and 83% after treatment. Results showed that 50.5% of the baseline and 29.5% of the follow-up samples were CTCcombo-positive. CTCscombo after treatment were associated with increased mortality after adjusting for FIGO stage (HR 2.574, 95% CI: 1.227-5.398, p = 0.012), a higher risk of recurrence after adjusting for peritoneal carcinosis (HR 4.068, 95% CI: 1.948-8.498, p < 0.001), and increased mortality after five survived years.

Discussion: The two-sided analytical approach revealed CTC subpopulations associated with ovarian cancer progression and may illuminate a potential treatment-related shift in molecular phenotypes. That approach can identify patients who have elevated risk of recurrence and death due to ovarian cancer and who may require risk-adapted treatment strategies.

Keywords: circulating tumor cells; long-term survival; primary epithelial ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

S.V. declares research support, advisory board, honoraria, and travel expenses from AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Pfizer, Roche, Sensor Kinesis, Teva, Tesaro. I.V. declares research support from Amgen, Roche, Oncoinventand Genmab and honoraria advisory boards from Amgen, AstraZeneca, Clovis Oncology Inc., -Carrick Therapeutics, Deciphera Pharmaceuticals, -Elevar Therapeutics, F. Hoffmann-La Roche, Genmab, GSK, Immunogen Inc., Jazzpharma, Mersana, MSD, Novocure, Octimet Oncology, Oncoinvent, Sotio, Verastem Oncology, Zentalis. J.S., A.R., L.L., L.W., N.C., B.B., and I.B., declare no conflicts of interest.

Figures

Figure 1
Figure 1
Concordance of PCR and IF in the 89 blood samples taken at baseline (a) and in the 57 blood samples taken at follow-up (b). The scatterplot (c) depicts the CTC numbers assessed by IF at baseline in PCR-positive and PCR-negative samples.
Figure 2
Figure 2
Kaplan–Meier plots showing the association of CTCcombo at baseline and follow-up. The patients are stratified into CTCcombo-positive and CTCcombo-negative after combining the results from IF and qPCR. The survival differences of CTCs at baseline (a,b) and at follow-up (c,d) are evaluated for statistical significance using the log-rank test.
See this image and copyright information in PMC

References

    1. De Angelis R., Sant M., Coleman M.P., Francisci S., Baili P., Pierannunzio D., Trama A., Visser O., Brenner H., Ardanaz E., et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE—5-a population-based study. Lancet Oncol. 2014;15:23–34. doi: 10.1016/S1470-2045(13)70546-1. - DOI - PubMed
    1. Baldwin L.A., Huang B., Miller R.W., Tucker T., Goodrich S.T., Podzielinski I., DeSimone C.P., Ueland F.R., van Nagell J.R., Seamon L.G. Ten-year relative survival for epithelial ovarian cancer. Obstet. Gynecol. 2012;120:612–618. doi: 10.1097/AOG.0b013e318264f794. - DOI - PubMed
    1. Hoppenot C., Eckert M.A., Tienda S.M., Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol. Oncol. 2018;148:204–212. doi: 10.1016/j.ygyno.2017.10.032. - DOI - PubMed
    1. Giannopoulou L., Kasimir-Bauer S., Lianidou E.S. Liquid biopsy in ovarian cancer: Recent advances on circulating tumor cells and circulating tumor DNA. Clin. Chem. Lab. Med. 2018;56:186–197. doi: 10.1515/cclm-2017-0019. - DOI - PubMed
    1. Obermayr E., Bednarz-Knoll N., Orsetti B., Weier H.U., Lambrechts S., Castillo-Tong D.C., Reinthaller A., Braicu E.I., Mahner S., Sehouli J., et al. Circulating tumor cells: Potential markers of minimal residual disease in ovarian cancer? A study of the OVCAD consortium. Oncotarget. 2017;8:106415–106428. doi: 10.18632/oncotarget.22468. - DOI - PMC - PubMed

LinkOut - more resources